Turnstone Biologics (Biotechnology, Health and Wellness) — Funding, Investors & Signals 2026

Turnstone Biologics

Developing next-generation TIL-based therapies to treat and cure solid tumors.

Founded 2015

San Diego, United States 64 employees Series D Total: $132.70M Biotechnology, Health and Wellness

Turnstone Biologics, a clinical-stage biotechnology company founded in 2015, is focused on developing next-generation TIL-based therapies to treat and cure solid tumors. The company's differentiated approach centers around pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy. This innovative therapy is based on the identification, selection, and expansion of the most potent tumor-reactive T cells, known as Selected TILs. Turnstone is actively progressing its most advanced program, TIDAL-01, which is currently undergoing evaluation in multiple Phase 1 studies for various cancer types, including colorectal cancer, breast cancer, head and neck cancer, uveal melanoma, and cutaneous melanoma. The company's focus on overcoming the limitations of first-generation bulk TIL therapy, which has shown objective responses only in limited tumor types, sets it apart in the industry. Turnstone is also advancing its preclinical pipeline programs, including TIDAL-02, the next Selected TIL program, and a program that combines TIDAL-01 with viral immunotherapy. As of July 14, 2021, Turnstone Biologics secured a significant $80.00M Series D investment, with key investors such as Versant Ventures, 60 Degree Capital, Brace Pharma Capital, JM Family Enterprises, Northleaf Capital Partners, Point72, Ridgeback Capital, Teralys Capital, PFM Health Sciences, and Surveyor Capital demonstrating strong support for the company's mission. With its headquarters in the United States, Turnstone Biologics is positioned to make meaningful strides in the biotechnology and health and wellness industries. For more information, please visit www.turnstonebio.com.

Funding Stage	Amount	Investors	Lead Investors	Date
Series D	••••••	10	•••• ••••	14 Jul 2021
Corporate Round	••••••	-		19 Dec 2019
Series C	••••••	-		07 Jan 2019
Series B	••••••	-		02 Nov 2016
Series A	••••••	-		27 Oct 2015

Funding Stage

Amount

Investors

Lead Investors

Date

Series D

••••••

•••• ••••

14 Jul 2021

Corporate Round

••••••

19 Dec 2019

Series C

••••••

07 Jan 2019

Series B

••••••

02 Nov 2016

Series A

••••••

27 Oct 2015

FAQ About Turnstone Biologics

Developing next-generation TIL-based therapies to treat and cure solid tumors.

Turnstone Biologics was founded in 2015.

Turnstone Biologics is headquartered in San Diego, United States.

Turnstone Biologics operates in the following industries: Biotechnology, Health and Wellness.

Turnstone Biologics has approximately 64 employees.

Turnstone Biologics has completed 5 funding rounds, raising a total of $132.70M. The latest funding stage is Series D.

Top alternatives and competitors to Turnstone Biologics include Grit Biotechnology, Iovance Biotherapeutics, Inc., Huasaiboman Medical Cell Biology, AgonOx, Inc., Genelux. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Turnstone Biologics and Grit Biotechnology are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Turnstone Biologics

General Information

Track Turnstone Biologics

Discover More

About Turnstone Biologics

Funding Rounds & Investors (5)

Turnstone Biologics Alternatives & Competitors

FAQ About Turnstone Biologics

Don't just browse. Track.